FISSCURE® obtains CE mark and launches in Europe with GrowthMedics FISSCURE® is a CE certified, innovative single-use medical device designed for the precise injection of botulinum toxin into the internal anal sphincter for the treatment of chronic anal fissure. The solution is developed by MD. Philippe Maerten, as he experienced challenges for both patients and healthcare professionals. FISSCURE® will offer a new faster and effective alternative for patients. “Being part of the launch of this one-of-a-kind new treatment method is very exciting. The solution addresses a specific condition and offers a strong alternative to current practices which are essentially ointments or surgery. Patients and healthcare professionals will strongly benefit from this solution. We look forward commercializing this technology across European healthcare clinics” – Emre Aykac (Managing Director, GrowthMedics).

“The treatment of anal fissures remains challenging for both healthcare providers and their patients. With the FISSCUREâ we want to revolutionize the approach on how to treat anal fissures and change the current paradigm. We belief that our collaboration with GrowthMedics will allow patients and healthcare providers to benefit quickly from our medical innovation.” – MD. Philippe Maerten (CEO, Doc Invent SA.) GrowthMedics will utilize its expertise and deep industry network, targeting partnerships with gastroenterologists and proctological surgeons, distributors as well as building a thought leader network across Europe. European sales contacts for clinics and distributors www.fisscure.com

Fisscure Sales Office Ellermanstraat 15F 1114 AK Amsterdam The Netherlands T: +31 85 107 4309 @: europe@fisscure.eu Headquarters Doc-Invent SA Chemin Riant-Pré 40 1010 Lausanne Switzerland

About GrowthMedics GrowthMedics is a market expansion provider assisting worldwide MedTech and IVD companies with their development in the European and Middle-Eastern market.